Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$100.74

4.94 (5.16%)

16:07
10/14/19
10/14
16:07
10/14/19
16:07

Reata Pharmaceuticals Part 2 MOXIe trial of omaveloxolone meets primary endpoint

Reata Pharmaceuticals announced that the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia, or FA, met its primary endpoint of change in the modified Friedreich's Ataxia Rating Scale, or mFARS, relative to placebo after 48 weeks of treatment. Patients treated with omaveloxolone demonstrated a statistically significant, placebo-corrected 2.40 point improvement in mFARS after 48 weeks of treatment. Omaveloxolone treatment was generally reported to be well-tolerated. Based on these results, and subject to discussions with regulatory authorities, the company plans to proceed with the submission of regulatory filings for marketing approval in the United States and internationally. Part 2 of MOXIe, an international, multi-center, double-blind, placebo-controlled, randomized registrational Phase 2 trial, enrolled 103 patients with FA at 11 study sites in the United States, Europe and Australia. Patients were randomized 1:1 to 150 mg of omaveloxolone or placebo. The primary analysis population included patients without pes cavus, a musculoskeletal foot deformity that may interfere with the patient's ability to perform some components of the mFARS exam. Safety analyses were evaluated in the all randomized population. The primary endpoint for the study was change in the mFARS score relative to placebo after 48 weeks of treatment. The mFARS is a physician-assessed neurological rating scale used to measure FA disease progression. It includes four sections that measure the patient's performance of activities such as speaking and swallowing, upper limb coordination, lower limb coordination, and standing and walking. The FDA has indicated that mFARS is an acceptable primary endpoint to evaluate the effect of omaveloxolone for the treatment of patients with FA. Omaveloxolone treatment met the primary endpoint of the study producing a statistically significant, placebo-corrected 2.40 point improvement in mFARS. Patients treated with omaveloxolone experienced a mean improvement in mFARS of -1.55 points from baseline, while patients treated with placebo experienced a mean worsening in mFARS of +0.85 points from baseline. The observed placebo-corrected improvements in mFARS were time-dependent, increasing over the course of treatment with the largest improvement observed after 48 weeks of treatment. Omaveloxolone treatment also improved the mFARS scores of patients with pes cavus. When the pes cavus patients are included in the analysis of the mFARS scores at Week 48, omaveloxolone treatment produced a mean statistically significant, placebo-corrected 1.93 point improvement in mFARS. Omaveloxolone treatment also improved several secondary endpoints included in the study. Four omaveloxolone patients and two placebo patients discontinued study drug due to an adverse event, or AE. The reported AEs were generally mild to moderate in intensity, and the most common AEs observed more frequently compared to placebo were headache, nausea, increased aminotransferases, fatigue and abdominal pain. Increases in aminotransferases are a pharmacological effect of omaveloxolone, which increases production of aminotransferases in vitro, and believed to be related to restoration of mitochondrial function. In MOXIe, the aminotransferase increases were associated with improvements in total bilirubin and were not associated with liver injury. The overall rate of serious adverse events, or SAEs, was low, with three patients in each group reporting SAEs while receiving study drug. Two additional omaveloxolone-treated patients reported SAEs approximately two weeks after receiving their final dose.

RETA Reata Pharmaceuticals
$100.74

4.94 (5.16%)

09/26/19
SBSH
09/26/19
NO CHANGE
SBSH
Buy
Citi opens 'Positive Catalyst Watch' on Reata Pharmaceuticals
Citi analyst Yigal Nochomovitz opened a 90-day "Positive Catalyst Watch" on Reata Pharmaceuticals ahead of the Phase 3 Cardinal data for bardoxolone in Alport syndrome expected in the second half of 2019. The analyst has a "high conviction" in Alport and expects the stock to be up ~50%-75% on positive data. He also expects investors to assign higher probabilities of success for bardoxolone in other rare nephropathies following the positive Alport data. He keeps a Buy rating on Reata shares.
09/26/19
NATL
09/26/19
INITIATION
Target $130
NATL
Buy
Reata Pharmaceuticals initiated with a Buy at National Securities
National Securities analyst Maria Barbera initiated Reata Pharmaceuticals with a Buy and $130 price target.
10/10/19
STFL
10/10/19
NO CHANGE
Target $135
STFL
Buy
Reata Pharmaceuticals 'bold move' should be well received by Street, says Stifel
Stifel analyst Adam Walsh notes that in "a bold move" likely to be well received by the Street, Reata Pharmaceuticals (RETA) reacquired ex-U.S. rights to BARD, OMAV, and other Nrf2 activators from AbbVie (ABBV) for total deal consideration of $330M. Given AbbVie's lack of a significant renal franchise, the reacquisition of ex-U.S. BARD rights restores strategic flexibility to Reata and provides the opportunity to either find a more engaging development partner, go it alone ex-U.S., or sell the company outright, he contends. Further, the analyst believes the deal terms look "highly reasonable" relative to potential ex-U.S. BARD sales. Walsh has a Buy rating and $135 price target on Reata's shares.
10/14/19
LEER
10/14/19
NO CHANGE
Target $180
LEER
Outperform
Reata Pharmaceuticals price target raised to $180 form $139 at SVB Leerink
SVB Leerink analyst Joseph Schwartz raised his price target for Reata Pharmaceuticals to $180 from $139, while reiterating an Outperform rating on the shares. The analyst believes Bardoxolone methyl remains a key growth driver for Reata with Phase.3 CARDINAL data expected near-term. Additional analysis since his CARDINAL preview suggests that a positive CARDINAL outcome has the potential to lift the stock by 25%-50% and that a valuation of $4B-$7B is reasonable post-data. Lastly, although Phase 3 CARDINAL data are expected after American Society of Nephrology Kidney Week, emerging evidence continues to dispel concerns of hyperfiltration, he contends.

TODAY'S FREE FLY STORIES

CLNY

Colony Capital

$4.99

-0.055 (-1.09%)

15:49
11/12/19
11/12
15:49
11/12/19
15:49
Hot Stocks
Digital Colony acquires Beanfield Technologies, terms not disclosed »

Digital Colony announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 10

    Dec

15:43
11/12/19
11/12
15:43
11/12/19
15:43
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

ET

Energy Transfer LP

$11.80

-0.18 (-1.50%)

15:38
11/12/19
11/12
15:38
11/12/19
15:38
Periodicals
FBI opens corruption probe of approval for Mariner East pipelines, AP says »

The FBI has begun a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWOU

2U

$22.27

0.46 (2.11%)

15:34
11/12/19
11/12
15:34
11/12/19
15:34
Options
2U options imply 21.4% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

AXAS

Abraxas Petroleum

$0.31

-0.0309 (-9.18%)

15:33
11/12/19
11/12
15:33
11/12/19
15:33
Hot Stocks
Abraxas Petroleum cancels Q3 earnings call scheduled for this afternoon »

Abraxas Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

15:25
11/12/19
11/12
15:25
11/12/19
15:25
General news
Treasury Market Summary »

Treasury Market Summary:…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.45

0.06 (0.02%)

15:20
11/12/19
11/12
15:20
11/12/19
15:20
Periodicals
POTUS advisers exploring 15% tax rate proposal for middle class, WP says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.45

0.06 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUYA

Huya

$24.33

-1 (-3.95%)

15:19
11/12/19
11/12
15:19
11/12/19
15:19
Options
HUYA options imply 14.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

SPY

SPDR S&P 500 ETF Trust

$308.49

0.1 (0.03%)

, SPX

S&P 500

$0.00

(0.00%)

15:18
11/12/19
11/12
15:18
11/12/19
15:18
General news
Kudlow says in 'very preliminary stages' of talks on possible tax cut proposal »

Larry Kudlow, Director of…

SPY

SPDR S&P 500 ETF Trust

$308.49

0.1 (0.03%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/12/19
11/12
15:17
11/12/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/12/19
11/12
15:16
11/12/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DASTY

Dassault Systemes

$0.00

(0.00%)

15:14
11/12/19
11/12
15:14
11/12/19
15:14
Conference/Events
Dassault Systemes to hold a meeting »

Life Sciences Day to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SYNA

Synaptics

$58.80

0.19 (0.32%)

15:13
11/12/19
11/12
15:13
11/12/19
15:13
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

SPY

SPDR S&P 500 ETF Trust

$308.41

0.02 (0.01%)

, SPX

S&P 500

$0.00

(0.00%)

15:11
11/12/19
11/12
15:11
11/12/19
15:11
General news
Kudlow says no tariff adjustments will be made unless there is trade deal »

Larry Kudlow, Director of…

SPY

SPDR S&P 500 ETF Trust

$308.41

0.02 (0.01%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$261.59

-0.57 (-0.22%)

15:10
11/12/19
11/12
15:10
11/12/19
15:10
Periodicals
Ex-HBO chief Plepler in talks to create original content for Apple TV+, WSJ says »

According to the Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$308.41

0.02 (0.01%)

, SPX

S&P 500

$0.00

(0.00%)

15:08
11/12/19
11/12
15:08
11/12/19
15:08
General news
Kudlow says President's key point was trade deal must be a 'good deal' for U.S. »

Economic adviser Larry…

SPY

SPDR S&P 500 ETF Trust

$308.41

0.02 (0.01%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$11.12

-0.73 (-6.16%)

15:04
11/12/19
11/12
15:04
11/12/19
15:04
Options
SmileDirectClub options imply 23.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$25.94

2.91 (12.64%)

15:02
11/12/19
11/12
15:02
11/12/19
15:02
Downgrade
Kemet rating change  »

Kemet downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TSLA

Tesla

$346.80

1.73 (0.50%)

14:55
11/12/19
11/12
14:55
11/12/19
14:55
Periodicals
Tesla CEO Musk says to build EU Gigafactory in 'Berlin area,' Bloomberg reports »

Bloomberg cites comments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.78

0.54 (8.65%)

14:54
11/12/19
11/12
14:54
11/12/19
14:54
Hot Stocks
PG&E announces extended deadline for filing fire claims in chapter 11 cases »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

AZUL

Azul

$35.23

-1.32 (-3.61%)

, EADSY

Airbus

$0.00

(0.00%)

14:52
11/12/19
11/12
14:52
11/12/19
14:52
Hot Stocks
Azul receives first Airbus A321neo in Brazil »

Azul (AZUL) received the…

AZUL

Azul

$35.23

-1.32 (-3.61%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKAMY

ThyssenKrupp

$0.00

(0.00%)

, BX

Blackstone

$51.89

-0.01 (-0.02%)

14:49
11/12/19
11/12
14:49
11/12/19
14:49
Periodicals
3G Capital among suitors for ThyssenKrupp's elevator unit, Bloomberg says »

Brazilian-American…

TKAMY

ThyssenKrupp

$0.00

(0.00%)

BX

Blackstone

$51.89

-0.01 (-0.02%)

CG

Carlyle Group

$27.74

0.24 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$21.26

-0.71 (-3.23%)

14:49
11/12/19
11/12
14:49
11/12/19
14:49
Options
Tilray options imply 21.1% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

DTIL

Precision BioSciences

$8.77

0.27 (3.18%)

14:44
11/12/19
11/12
14:44
11/12/19
14:44
Conference/Events
Precision BioSciences participates in a conference call with BTIG »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 07

    Dec

FGEN

FibroGen

$33.38

-1.99 (-5.63%)

, AZN

AstraZeneca

$47.17

0.29 (0.62%)

14:33
11/12/19
11/12
14:33
11/12/19
14:33
Recommendations
FibroGen, AstraZeneca analyst commentary  »

Jefferies doesn't…

FGEN

FibroGen

$33.38

-1.99 (-5.63%)

AZN

AstraZeneca

$47.17

0.29 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 18

    Nov

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.